The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates
| Autor: | Dorota Kendler, Wolfgang Horninger, Christian Uprimny, Irene Virgolini, Katharina Fink, Peter Lukas, Sabine Buxbaum, Leonhard Gruber, Clemens Decristoforo, Lorenza Scarpa, Jasmin Bektic |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
business.industry
General Medicine Castration resistant medicine.disease 030218 nuclear medicine & medical imaging 03 medical and health sciences Prostate cancer 0302 clinical medicine medicine.anatomical_structure 030220 oncology & carcinogenesis Absorbed dose medicine Dosimetry Radiology Nuclear Medicine and imaging Ct diagnosis business Nuclear medicine Prospective cohort study Lymph node Progressive disease |
| Zdroj: | European Journal of Nuclear Medicine and Molecular Imaging. 44:788-800 |
| ISSN: | 1619-7089 1619-7070 |
| DOI: | 10.1007/s00259-016-3609-9 |
| Popis: | A targeted theragnostic approach based on increased expression of prostate-specific membrane antigen (PSMA) on PC cells is an attractive treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Ten consecutive mCRPC patients were selected for 177Lu-PSMA617 therapy on the basis of PSMA-targeted 68Ga-PSMA-HBED-CC PET/CT diagnosis showing extensive and progressive tumour load. Following dosimetry along with the first therapy cycle restaging (68Ga-PSMA-HBED-CC and 18F-NaF PET/CT) was performed after 2 and 3 therapy cycles (each 6.1 ± 0.3 GBq, range 5.4–6.5 GBq) given intravenously over 30 minutes, 9 ± 1 weeks apart. PET/CT scans were compared to 177Lu-PSMA617 24-hour whole-body scans and contrast-enhanced dual-phase CT. Detailed comparison of SUVmax values and absorbed tumour doses was performed. 177Lu-PSMA617 dosimetry indicated high tumour doses for skeletal (3.4 ± 1.9 Gy/GBq; range 1.1–7.2 Gy/GBq), lymph node (2.6 ± 0.4 Gy/GBq; range 2.3–2.9 Gy/GBq) as well as liver (2.4 ± 0.8 Gy/GBq; range 1.7–3.3 Gy/GBq) metastases whereas the dose for tissues/organs was acceptable in all patients for an intention-to-treat activity of 18 ± 0.3 GBq. Three patients showed partial remission, three mixed response, one stable and three progressive disease. Decreased 177Lu-PSMA617 and 68Ga-PSMA-HBED-CC uptake (mean SUVmax values 20.2 before and 15.0 after 2 cycles and 11.5 after 3 cycles, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|